WFDC2 and ovarian cancer: In a study of 120 cases of ovarian cancer, patients in the lobaplatin group had significantly lower levels of HE4 and CA125 than those in the carboplatin group when examined at 3 or 6 months after chemotherapy (P < 0.05) [30].